APOA1 / ApoAI Protein (His Tag)

17.04.2013

Sino Biological Inc. liefert APOA1 / ApoAI Protein (His Tag) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über APOA1 / ApoAI Protein (His Tag) lesen Sie bitte: http://www.sinobiological.com/APOA1-Protein-a-2595.html

Produkt-Information von APOA1 / ApoAI Protein

Synonym	APOA1
Protein Construction	A DNA sequence encoding the mature form of human APOA1 (P02647) (Asp25-Gln267) was expressed with a polyhistidine tag at the N-terminus.
Source	Human
Expression Host	E.coli

QC Testing von APOA1 / ApoAI Protein

Purity	> 95 % as determined by SDS-PAGE	SDS-PAGE: APOA1 protein
Endotoxin	Please contact us for more information.
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	His
Molecular Mass	The recombinant human APOA1 consists of 263 amino acids and predicts a molecular mass of 30.7 KDa. It migrates as an approximately 27-31 KDa band in SDS-PAGE under reducing conditions.
Formulation	Lyophilized from sterile PBS, 10% Glycerol, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide von APOA1 / ApoAI Protein

Storage	Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Beschreibung von APOA1 / ApoAI Protein

Apolipoprotein A-I (ApoA-I) is the major protein component of high density lipoprotein (HDL) in plasma. This protein promotes cholesterol efflux from tissues to the liver and thus helps to clear cholesterol from arteries Acting as a cofactor for lecithin cholesterolacyltransferase (LCAT), ApoA-I is involved in the formation of most plasma cholesteryl esters. ApoA-I is also identified as a prostacyclin (PGI2) stabilizing factor, and thus may have an anti-clotting effect. Defects in this gene resulted in HDL deficiencies, including Tangier disease and systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA-I is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

References

Brewer HB Jr. et al., 1978, Biochem Biophys Res Commun. 80: 623-30.
Soutar AK. et al., 1992, Proc Natl Acad Sci. 89: 7389-93.
Eggerman TL. et al., 1991, J Lipid Res. 32: 821-8.
Voyiaziakis E. et al., 1998. J Lipid Res. 39: 313-21.